KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Share-based Compensation: 2011-2024

Historic Share-based Compensation for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $12.0 million.

  • Esperion Therapeutics' Share-based Compensation fell 22.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 15.03%. This contributed to the annual value of $12.0 million for FY2024, which is 0.29% up from last year.
  • Esperion Therapeutics' Share-based Compensation amounted to $12.0 million in FY2024, which was up 0.29% from $12.0 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Share-based Compensation registered a high of $28.4 million during FY2020, and its lowest value of $12.0 million during FY2023.
  • Over the past 3 years, Esperion Therapeutics' median Share-based Compensation value was $12.0 million (recorded in 2024), while the average stood at $13.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first rose by 9.66% in 2020, then tumbled by 37.40% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Share-based Compensation (Yearly) stood at $28.4 million in 2020, then declined by 14.37% to $24.3 million in 2021, then slumped by 37.40% to $15.2 million in 2022, then declined by 21.41% to $12.0 million in 2023, then climbed by 0.29% to $12.0 million in 2024.